Organisation paid for research Program year 2023 Source: CMS Open Payments

Kaiser Foundation Research

Neither a doctor nor a teaching hospital

Research payments

$2,091,276

106 payments

Through program year 2023, Kaiser Foundation Research is reported as receiving $2,091,276 in research payments, across 106 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$569,610	51
2022	Research	$292,662	20
2021	Research	$862,751	15
2020	Research	$231,501	11
2019	Research	$134,752	9

Breakdown

Who paid Research payments · program years 2019–2023

GlaxoSmithKline, LLC. $1,360,546 39 payments
ViiV Healthcare Company $664,542 53 payments
Takeda Pharmaceuticals U.S.A., Inc. $51,388 10 payments
Agios Pharmaceuticals, Inc. $14,800 4 payments

Studies the money was for Research payments · program years 2019–2023

A Retrospective Cohort Study Investigating the Incidence of Maternal, $776,518 5 payments
A Qualitative Hybrid III Implementation Study to Identify and Evaluate $509,194 23 payments
Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $429,478 26 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $147,253 25 payments
Ho-18-18806 - Longitudinal Continuity of Care Assessment Within An Idn $116,482 3 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $34,688 4 payments
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Mln9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma $26,150 5 payments
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Mln9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma $25,238 5 payments
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation $14,800 4 payments
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No $8,095 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.